Nicolas Tilmans

Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation.

Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation.

Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation.

Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation.